This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

MaterialsVideos
Chronic inflammatory demyelinating polyneuropathy (CIDP)CIDP is a progressive illness caused by an autoimmune attack on myelin, resulting in demyelination. It impacts sensory and motor symptoms. Patients often experience overall muscle weakness and damaged deep tendon reflexes that may be so profound that walking is inhibited. In severe cases where denervation of the respiratory muscles occurs, death may result. Although CIDP can occur at all ages, it is more prevalent in older individuals and in males.1,2Materials

View materials for you and your patients

Videos

Find videos and on-demand webinars

References:
  1. Neurology and Neurosurgery. Johns Hopkins Medicine. Accessed May 31, 2022. https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/peripheral_nerve/conditions/guillain_barre_and_cidp.html
  2. Canadian Agency for Drugs and Technologies in Health. Immunomodulatory drugs and intravenous immunoglobulin (IVIg) for patients with chronic demyelinating polyneuropathy who are in remission: a review of clinical and cost-effectiveness and guidelines [internet]. 2015 Mar 13. Accessed May 31, 2022. https://www.ncbi.nlm.nih.gov/books/NBK349794/

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-CIN-USA-0002
You are now leaving Pfizer
 
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
 
PP-MCL-USA-0367